Antibiotics (Mar 2023)

Predictive Factors of Piperacillin Exposure and the Impact on Target Attainment after Continuous Infusion Administration to Critically Ill Patients

  • Javier Martínez-Casanova,
  • Erika Esteve-Pitarch,
  • Helena Colom-Codina,
  • Víctor Daniel Gumucio-Sanguino,
  • Sara Cobo-Sacristán,
  • Evelyn Shaw,
  • Kristel Maisterra-Santos,
  • Joan Sabater-Riera,
  • Xosé L. Pérez-Fernandez,
  • Raül Rigo-Bonnin,
  • Fe Tubau-Quintano,
  • Jordi Carratalà,
  • Ariadna Padullés-Zamora

DOI
https://doi.org/10.3390/antibiotics12030531
Journal volume & issue
Vol. 12, no. 3
p. 531

Abstract

Read online

Critically ill patients undergo significant pathophysiological changes that affect antibiotic pharmacokinetics. Piperacillin/tazobactam administered by continuous infusion (CI) improves pharmacokinetic/pharmacodynamic (PK/PD) target attainment. This study aimed to characterize piperacillin PK after CI administration of piperacillin/tazobactam in critically ill adult patients with preserved renal function and to determine the empirical optimal dosing regimen. A total of 218 piperacillin concentrations from 106 patients were simultaneously analyzed through the population PK approach. A two-compartment linear model best described the data. Creatinine clearance (CLCR) estimated by CKD-EPI was the covariate, the most predictive factor of piperacillin clearance (CL) interindividual variability. The mean (relative standard error) parameter estimates for the final model were: CL: 12.0 L/h (6.03%); central and peripheral compartment distribution volumes: 20.7 L (8.94%) and 62.4 L (50.80%), respectively; intercompartmental clearance: 4.8 L/h (26.4%). For the PK/PD target of 100% fT>1×MIC, 12 g of piperacillin provide a probability of target attainment > 90% for MIC CR, but higher doses are needed for MIC = 16 mg/L when CLCR > 100 mL/min. For 100% fT>4×MIC, the highest dose (24 g/24 h) was not sufficient to ensure adequate exposure, except for MICs of 1 and 4 mg/L. Our model can be used as a support tool for initial dose guidance and during therapeutic drug monitoring.

Keywords